Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)
Overview
Authors
Affiliations
Purpose: To determine the specific types, durations, and intensities of recreational physical activity associated with the greatest improvements in disease-free survival (DFS) of patients with colon cancer.
Methods: We conducted a prospective cohort study nested within a randomized multicenter trial of stage III colon cancer that compared 3 versus 6 months of fluorouracil, leucovorin, and oxaliplatin with or without celecoxib. We measured recreational physical activity in the first 3 months of chemotherapy and again 6 months after completion of chemotherapy. The primary end point was DFS.
Results: During a median follow-up of 5.9 years, 457 of 1,696 patients experienced disease recurrence or death. For total recreational physical activity volume, the 3-year DFS was 76.5% with < 3.0 metabolic equivalent task hours per week (MET-h/wk) and 87.1% with ≥ 18.0 MET-h/wk (risk difference [RD], 10.6%; 95% CI, 4.7 to 19.4; < .001). For light-intensity to moderate-intensity activities, the 3-year DFS was 65.7% with 0.0 h/wk and 87.1% with ≥ 1.5 h/wk (RD, 21.4%; 95% CI, 9.2 to 37.1; < .001). For vigorous-intensity activity, the 3-year DFS was 76.0% with 0.0 h/wk and 86.0% with ≥ 1.0 h/wk (RD, 10.0%; 95% CI, 4.5 to 18.9; < .001). For brisk walking, the 3-year DFS was 81.7% with < 1.0 h/wk and 88.4% with ≥ 3.0 h/wk (RD, 6.7%; 95% CI, 3.0 to 13.8; < .001). For muscle strengthening activity, the 3-year DFS was 81.8% with 0.0 h/wk and 88.8% for ≥ 0.5 h/wk (RD, 7.0%; 95% CI, 3.1 to 14.2; = .003).
Conclusion: Among patients with stage III colon cancer enrolled in a trial of postoperative treatment, larger volumes of recreational physical activity, longer durations of light- to moderate-intensity aerobic physical activity, or any vigorous-intensity aerobic physical activity were associated with the greatest improvements in DFS.
Brown J, Ma C, Shi Q, Saltz L, Shields A, Meyerhardt J Cancer. 2025; 131(5):e35727.
PMID: 39989023 PMC: 11848238. DOI: 10.1002/cncr.35727.
Brown J, Ma C, Shi Q, Couture F, Kuebler P, Kumar P J Natl Cancer Inst. 2024; 116(12):2032-2039.
PMID: 39180477 PMC: 11630502. DOI: 10.1093/jnci/djae203.
Baicalin Prevents Colon Cancer by Suppressing CDKN2A Protein Expression.
Li G, Chu X, Xing Y, Xue X, Ihtisham B, Liang X Chin J Integr Med. 2024; 30(11):1007-1017.
PMID: 38941045 DOI: 10.1007/s11655-024-4109-6.
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).
Pericay C, Montagut C, Reina J, Melian M, Alcaide J, Tarazona N Clin Transl Oncol. 2024; 26(11):2812-2825.
PMID: 38914755 PMC: 11467085. DOI: 10.1007/s12094-024-03559-5.
Herrero Lopez B, Cardena-Gutierrez A, Godoy Ortiz A, Gonzaga Lopez A, Grueso Lopez A, Nuno Alves A Clin Transl Oncol. 2024; 27(1):108-116.
PMID: 38909323 PMC: 11735567. DOI: 10.1007/s12094-024-03546-w.